Department of Medicine, Children's Hospital Boston, Boston, MA 02115, USA.
N Engl J Med. 2011 Sep 1;365(9):807-14. doi: 10.1056/NEJMoa1103070.
An improved understanding of the regulation of the fetal hemoglobin genes holds promise for the development of targeted therapeutic approaches for fetal hemoglobin induction in the β-hemoglobinopathies. Although recent studies have uncovered trans-acting factors necessary for this regulation, limited insight has been gained into the cis-regulatory elements involved.
We identified three families with unusual patterns of hemoglobin expression, suggestive of deletions in the locus of the β-globin gene (β-globin locus). We performed array comparative genomic hybridization to map these deletions and confirmed breakpoints by means of polymerase-chain-reaction assays and DNA sequencing. We compared these deletions, along with previously mapped deletions, and studied the trans-acting factors binding to these sites in the β-globin locus by using chromatin immunoprecipitation.
We found a new (δβ)(0)-thalassemia deletion and a rare hereditary persistence of fetal hemoglobin deletion with identical downstream breakpoints. Comparison of the two deletions resulted in the identification of a small intergenic region required for γ-globin (fetal hemoglobin) gene silencing. We mapped a Kurdish β(0)-thalassemia deletion, which retains the required intergenic region, deletes other surrounding sequences, and maintains fetal hemoglobin silencing. By comparing these deletions and other previously mapped deletions, we elucidated a 3.5-kb intergenic region near the 5' end of the δ-globin gene that is necessary for γ-globin silencing. We found that a critical fetal hemoglobin silencing factor, BCL11A, and its partners bind within this region in the chromatin of adult erythroid cells.
By studying three families with unusual deletions in the β-globin locus, we identified an intergenic region near the δ-globin gene that is necessary for fetal hemoglobin silencing. (Funded by the National Institutes of Health and others.).
对胎儿血红蛋白基因调控的深入了解有望为开发针对β-血红蛋白病中胎儿血红蛋白诱导的靶向治疗方法提供帮助。虽然最近的研究已经揭示了这种调控所需的反式作用因子,但对涉及的顺式调控元件的了解却很有限。
我们鉴定了三个具有异常血红蛋白表达模式的家系,提示β-珠蛋白基因(β-珠蛋白基因座)的缺失。我们通过比较基因组杂交来定位这些缺失,并通过聚合酶链反应检测和 DNA 测序来确认断点。我们比较了这些缺失,以及以前定位的缺失,并通过染色质免疫沉淀研究了与β-珠蛋白基因座这些位点结合的反式作用因子。
我们发现了一个新的(δβ)(0)-地中海贫血缺失和一个罕见的遗传性胎儿血红蛋白持续存在缺失,它们具有相同的下游断点。对这两个缺失的比较导致了一个小的基因间区域的鉴定,该区域对于γ-珠蛋白(胎儿血红蛋白)基因沉默是必需的。我们定位了一个库尔德β(0)-地中海贫血缺失,它保留了必需的基因间区域,删除了其他周围序列,并保持胎儿血红蛋白沉默。通过比较这些缺失和其他以前定位的缺失,我们阐明了δ-珠蛋白基因 5'端附近的一个 3.5kb 的基因间区域,该区域对于γ-珠蛋白沉默是必需的。我们发现,一个关键的胎儿血红蛋白沉默因子,BCL11A,及其伙伴在成人红细胞的染色质中结合在这个区域内。
通过研究三个具有β-珠蛋白基因座异常缺失的家系,我们鉴定了一个位于δ-珠蛋白基因附近的基因间区域,该区域对于胎儿血红蛋白沉默是必需的。(由美国国立卫生研究院和其他机构资助)。